What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Radiation therapy
His scientific interests lie mostly in Radiation therapy, Lung cancer, Radiology, Nuclear medicine and Surgery.
His Radiation therapy study introduces a deeper knowledge of Internal medicine.
His study in Lung cancer is interdisciplinary in nature, drawing from both Amifostine, Carcinoma, Randomized controlled trial and Pneumonitis.
His Radiology research is multidisciplinary, incorporating perspectives in Esophagus and Diaphragm.
His Nuclear medicine research includes themes of Breathing, Radiation treatment planning, Proton therapy and Tomography.
His work deals with themes such as Mesothelioma and Extrapleural Pneumonectomy, which intersect with Surgery.
His most cited work include:
- Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non–Small-Cell Lung Cancer (300 citations)
- Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT) (293 citations)
- Assessing Respiration-Induced Tumor Motion and Internal Target Volume Using Four-Dimensional Computed Tomography for Radiotherapy of Lung Cancer (263 citations)
What are the main themes of his work throughout his whole career to date?
Radiation therapy, Lung cancer, Internal medicine, Oncology and Nuclear medicine are his primary areas of study.
His research investigates the connection between Radiation therapy and topics such as Cancer that intersect with issues in Cancer research.
In his study, Common Terminology Criteria for Adverse Events is inextricably linked to Pneumonitis, which falls within the broad field of Lung cancer.
His Oncology study integrates concerns from other disciplines, such as Multivariate analysis, Single-nucleotide polymorphism and Clinical trial.
His Nuclear medicine research incorporates themes from Lung volumes, Lung, Radiation treatment planning and Proton therapy.
Zhongxing Liao has included themes like Esophagus and Toxicity in his Radiology study.
He most often published in these fields:
- Radiation therapy (49.06%)
- Lung cancer (40.33%)
- Internal medicine (39.09%)
What were the highlights of his more recent work (between 2018-2021)?
- Lung cancer (40.33%)
- Internal medicine (39.09%)
- Radiation therapy (49.06%)
In recent papers he was focusing on the following fields of study:
Zhongxing Liao spends much of his time researching Lung cancer, Internal medicine, Radiation therapy, Proton therapy and Cancer.
His studies deal with areas such as Locally advanced, Chemotherapy, Logistic regression and Randomized controlled trial as well as Lung cancer.
Zhongxing Liao interconnects Gastroenterology and Oncology in the investigation of issues within Internal medicine.
His research integrates issues of Nuclear medicine, Intensive care medicine, Proportional hazards model, Toxicity and Heart disease in his study of Radiation therapy.
Proton therapy is a subfield of Radiology that Zhongxing Liao investigates.
As part of the same scientific family, Zhongxing Liao usually focuses on Cancer, concentrating on Stage and intersecting with Common Terminology Criteria for Adverse Events and Chemoradiotherapy.
Between 2018 and 2021, his most popular works were:
- Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 Trial. (40 citations)
- Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer (38 citations)
- Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer (25 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Surgery
The scientist’s investigation covers issues in Radiation therapy, Proton therapy, Internal medicine, Lung cancer and Nuclear medicine.
His biological study spans a wide range of topics, including Cancer, Randomized controlled trial, Proportional hazards model, Lung and Prospective cohort study.
His study connects Oncology and Internal medicine.
As a part of the same scientific study, he usually deals with the Oncology, concentrating on Pneumonitis and frequently concerns with Immunotherapy.
His Lung cancer research is multidisciplinary, incorporating elements of Radiology, Tetraspanin, Disease and Cancer research.
Zhongxing Liao has researched Nuclear medicine in several fields, including Segmentation, Relative biological effectiveness and Automatic segmentation.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
